Skip to content

Satiating Diet, Appetite Control and Body Weight Loss in Individuals With Obesity

Non-restrictive Approach to Facilitate Appetite Control and Long-term Body Weight Loss in Individuals With Obesity: Can we do Better?

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05141526
Enrollment
234
Registered
2021-12-02
Start date
2022-01-15
Completion date
2025-11-01
Last updated
2023-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appetite Control, Weight Loss, Weight Maintenance

Brief summary

The objective of this study is to evaluate (1) the effect of a non-restrictive satiating intervention on appetite control, body weight loss and maintenance; and (2) determine whether switching to a non-restrictive satiating intervention following a conventional restrictive intervention can prevent increases in appetite and attenuate body weight regain usually observed after weight loss in men and women living with obesity. This is an 18-month, randomized, controlled, parallel weight loss \[Phase 1 (P1): 6 months\] and maintenance trial \[Phase 2 (P2): 12 months\] with three groups (n=234 men and women): (1) non-restrictive, satiating intervention (P1) followed by a continuation of this intervention (P2); (2) conventional restrictive intervention (-500 kcal/d) (P1) followed by a non-restrictive satiating intervention (P2); (3) control group that follows minimal healthy guidelines (P1) followed by recommended weight maintenance strategies (P2). All groups will be controlled for physical activity and sleep patterns. The non-restrictive satiating intervention will include guidelines and recipes to prepare highly satiating meals that will be low in energy density and glycemic index and high in protein, polyunsaturated fats, vitamins and minerals (e.g. calcium), and certain constituents of spices (e.g. capsaicin). Measurements at baseline (week 0), after P1 and P2 will include the following primary outcomes: appetite control, weight loss and maintenance; and secondary outcomes: body composition, physiological, psycho and neurobehavioural and health-related variables. Follow-ups will be done by a dietitian every 2 weeks during P1 and once a month during P2.

Interventions

OTHERNon-restrictive satiating intervention

Diet group containing satiating foods

OTHERConventional restrictive intervention + non-restrictive satiating intervention

Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase

OTHERControl group

This group will receive minimal healthy guidelines

Sponsors

University of Ottawa
CollaboratorOTHER
Laval University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Blinding participants is not possible due to the nature of the interventions. Individuals independent from the study and blinded to groups (e.g. statistician), will conduct the randomization and analyses while a research assistant, instructed not to discuss treatments with participants, will conduct the testing sessions.

Intervention model description

(1) non-restrictive, satiating intervention (P1) followed by a continuation of this intervention (P2); (2) conventional restrictive intervention (-500 kcal/d) (P1) followed by a non-restrictive satiating intervention (P2); (3) control group that follows minimal healthy guidelines (P1) followed by recommended weight maintenance strategies (P2). \*P1=phase 1; P2=phase 2

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* individuals with a BMI ≥30 and \<40 kg/m2 * aged between 18-50 years * waist circumference \>102 cm in men and \>88 cm in women.

Exclusion criteria

* taking medications that could influence appetite or body weight (e.g. thyroid replacement therapy, sulfonylureas and glucocorticoids) * being treated with insulin for type 2 diabetes * large body weight fluctuations (\>4 kg over last two months) * characterized by high restraint behaviour (score \>12, measured with the TFEQ) * history of an eating disorder (e.g. binge eating disorder) using the EDE questionnaire * performing \>150 min of moderate-vigorous intensity physical activity/week * use of nutritional supplements (multivitamins, calcium, protein, fibre); 8) smoking, drugs or alcohol (\>2 drinks/d) * consumption of \>5 cups of coffee/d * (pre)menopausal or pregnant women * diagnosis of chronic diseases, acute infections or gastric problems (e.g. ulcers) * food allergies/intolerances to ingredients/foods in the satiating intervention * having a pacemaker (for fMRI) * taking sedatives or sleeping pills * symptoms of depression (\>20 on the BDI).

Design outcomes

Primary

MeasureTime frameDescription
Body weight6 monthsBody weight loss (kg) after Phases 1 and 2
Body composition6 monthsBody fat (using dual x-ray absorptiometry)
Hunger/Satiety6 monthsusing a visual analogue scale and measured in mm
Energy intake6 monthsmeasured at an ad libitum meal in kilocalories

Secondary

MeasureTime frameDescription
Lipids (HDL-cholesterol, LDL-cholesterol, triglycerides, total cholesterol)18 monthsmeasured in mmol/L
Blood pressure18 monthsmmHg
Stress18 monthsState-Trait Anxiety Inventory
neurobehavioural variables6 monthsbrain anatomy and activity in response to food cues (using fMRI)
Diet satisfaction18 monthsDiet Satisfaction Questionnaire (scale: strongly disagree to strongly agree)
Anxiety18 monthsPerceived Stress Scales
Eating Behaviours18 monthsThree Factor Eating Behaviour Questionnaire
Depression Symptoms18 monthsBeck Depression Inventory

Countries

Canada

Contacts

Primary ContactVicky Drapeau, PhD
vicky.drapeau@fse.ulaval.ca4186562131
Backup ContactLucie Brunelle, MSc, RD
lucie.brunelle@kin.ulaval.ca4186562131

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026